KraneShares CSI China Internet ETF vs Koninklijke Philips NV — how do they compare? KraneShares CSI China Internet ETF trades at $24.92 (market cap $4.37B), while Koninklijke Philips NV trades at $24.22 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 5.4× KraneShares CSI China Internet ETF's market cap, and Koninklijke Philips NV pays a 4.17% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Koninklijke Philips NV for 84 Days on average.
| KWEB | PHG | |
|---|---|---|
Market Cap | $4.37B | $23.52B |
Volume | 13,393,361 | 1,635,069 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $32.91 |
52-Week Low | $23.63 | $23.81 |
Typical Hold Time | 57 Days | 84 Days |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.87, up 2.22% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell, while oscillators are neutral. Recent news highlights institutional activity, including a stake reduction by Tidal Investments LLC and an increase by HSBC Holdings PLC, amid ongoing U.S.-China trade dynamics and economic data releases.
The outlook for KWEB is clouded by geopolitical tensions and economic headwinds in China, though corporate profit growth offers a potential catalyst. Key risks include trade policy shifts and weak domestic consumption. Investors should weigh institutional movements against broader market sentiment for balanced exposure.
PHG trades at $24.225, up 0.56% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent news highlights Philips' innovation in healthcare technology including new product launches and strategic partnerships.
While valuation appears reasonable with P/E of 18.94 and EV/EBITDA of 8.86, the stock faces headwinds from bearish technical indicators and mixed analyst sentiment. Investment opportunity lies in continued earnings momentum and healthcare technology leadership, balanced against competitive pressures and execution risks in a challenging market environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →